Business
SPECTRAL OBTAINS EXCLUSIVE CANADIAN DISTRIBUTION RIGHTS FOR TORAYMYXIN?
SPECTRAL OBTAINS EXCLUSIVE CANADIAN DISTRIBUTION RIGHTS FOR TORAYMYXIN¿
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n Nov. 22, 2010 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nTORONTO, Nov. 22 /CNW/ - Spectral Diagnostics Inc., (TSX:SDI), today announced that it has signed a long-term, exclusive distribution\n agreement with Toray Industries, Inc. and Toray Medical Co., Ltd. of\n Japan (collectively "Toray") to market and sell Toraymyxin™ in Canada.\n Toraymyxin™ is a therapeutic hemoperfusion device that removes\n endotoxin, which can cause sepsis, from the bloodstream. This product\n and Spectral's EAA™ diagnostic, which measures endotoxin and identifies\n patients for treatment, are already approved for sale by Health Canada.\n\n\n"We are very pleased to have secured the Canadian distribution rights\n for this product. In conjunction with the U.S. license agreement signed\n last year, Spectral now has exclusive access to a potential North\n American market in excess of $1 billion," said Anthony Businskas,\n Executive Vice President and CFO of Spectral.\n\n\n"This expansion of market jurisdictions further confirms our strong\n business relationship with Toray and the outstanding market opportunity\n for this unique treatment for severe sepsis, combining our proprietary\n EAA™ diagnostic with the Toraymyxin™ therapeutic. We expect to begin\n market development activities in Canada during 2011," added Dr. Paul\n Walker, President and CEO of Spectral.\n\n\nAbout Spectral Diagnostics\n\n\nSpectral is a Phase III company see...